Low-density lipoprotein cholesterol levels and treatment intensity in secondary prevention of patients with ischaemic heart disease in the primary care setting: a real-world data registry study.

dc.contributor.authorSánchez Ruano, Núria
dc.contributor.authorFibla Matamoros, Anna
dc.contributor.authorFalces Salvador, Carles
dc.contributor.authorSánchez, Encarna
dc.contributor.authorSisó Almirall, Antoni
dc.contributor.authorGonzález de Paz, Luis
dc.date.accessioned2026-01-22T17:10:55Z
dc.date.available2026-01-22T17:10:55Z
dc.date.issued2025-07-23
dc.date.updated2026-01-22T17:10:55Z
dc.description.abstractBackground: Monitoring low-density lipoprotein cholesterol (LDL-C) and prescribing appropriate treatment is crucial for secondary prevention in primary care. Aim: To study LDL-C levels and treatments for patients with ischaemic heart disease according to target recommendations and assess factors influencing prescribed drug intensity. Design & setting: A cross-sectional study was undertaken. We examined electronic health records of patients with ischaemic heart disease from three primary care centres in Spain. Method: LDL-C levels were assessed using the most recent registry, and LDL-C-lowering treatments were categorised by their theoretical efficacy. Factors associated with LDL-C target attainment were analysed using univariate and multivariate regression models. Prescription intensity was studied with ordinal logistic regression models. Results: We studied 1936 patients, 14.88% of whom received no LDL-C-lowering treatment. The percentages of patients who achieved LDL-C thresholds of<70 mg/dl and<55 mg/dl were 35.0% and 12.65%, respectively. The factor associated with the <55 mg/dl threshold was type 2 diabetes mellitus (odds ratio [OR] 0.55, 95% confidence interval [CI] = 0.42 to 0.73), with males showing better LDL-C levels (OR 0.34, 95% CI = 0.23 to 0.51). Males had higher-intensity prescriptions (OR 1.57, 95% CI = 1.27 to 1.94) and older patients had lower-intensity treatments (OR 0.96, 95% CI = 0.95 to 0.97). Conclusion: Increased LDL-C drug treatment improvement, monitoring, and adherence to guideline recommendations are necessary for patients with ischaemic heart disease. Sex and age are potential factors associated with inadequate lipid-lowering treatment intensity and poor LDL-C control that might worsen cardiovascular outcomes in high-risk patients, leading to avoidable inequity among patients who visit the primary health setting.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec762683
dc.identifier.issn0960-1643
dc.identifier.pmid40074282
dc.identifier.urihttps://hdl.handle.net/2445/225984
dc.language.isoeng
dc.publisherThe College
dc.relation.isformatofhttps://doi.org/10.3399/BJGPO.2024.0220
dc.relation.ispartofBritish Journal of General Practice, 2025, vol. 9, num.2
dc.relation.urihttps://doi.org/10.3399/BJGPO.2024.0220
dc.rightscc-by (c) Sánchez Ruano, Núria et al., 2025
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties del cor
dc.subject.classificationLípids
dc.subject.classificationColesterol
dc.subject.otherHeart diseases
dc.subject.otherLipids
dc.subject.otherCholesterol
dc.titleLow-density lipoprotein cholesterol levels and treatment intensity in secondary prevention of patients with ischaemic heart disease in the primary care setting: a real-world data registry study.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
907783.pdf
Mida:
1.12 MB
Format:
Adobe Portable Document Format